Developer docs
API playgroundTry for free, no card

Search company profiles

Medinfar

Full company profile

uuid000pnkr

Namestring
Medinfar
Legal namestring
Laboratório Medinfar – Produtos Farmacêuticos, S.A.
Websiteurl
medinfar.pt
Company typeenum
Private
Founded yearint
1970
Descriptiontext

Grupo Medinfar is a Portuguese-origin pharmaceutical company founded in 1970, headquartered in Amadora, Portugal, with direct operations in Portugal and Morocco and export reach to 70+ countries. The group manufactures and markets both proprietary and partnered pharmaceutical brands across therapeutic areas including Consumer Health, Dermatology, Endocrinology, Respiratory, and Veterinary, holding more than 800 product registrations worldwide and producing 40 million units in 2023. Its corporate structure spans wholly-owned subsidiaries covering manufacturing (Medinfar Manufacturing S.A.), consumer health (Medinfar Consumer Health Lda.), veterinary and immunological products (Medinfar Sorológico S.A.), generics (Genéricos Portugueses Lda.), and shared services (Medinfar Serviços Lda.). Medinfar holds the #1 position in Portugal in the Consumer Health and Dermatology category and ranks 3rd largest among Portugal's top 5 pharmaceutical companies.

The business model combines four revenue streams: own-brand pharmaceutical products (primarily in Consumer Health and Dermatology), partnered-brand manufacturing and marketing, contract manufacturing for third-party clients, and international licensing-out of products through local partners who manage in-country commercialization. Manufacturing is anchored by an industrial facility in Condeixa-a-Nova currently undergoing a €33.8M modernization under the Portugal 2030/COMPETE 2030 program, with €5.07M of EU co-financing, targeting €63M in post-expansion sales and the creation of 66 new jobs. In-house R&D focuses on new formulations, production processes, and analytical methodologies. Quality and regulatory infrastructure includes ISO 9001, 14001, and 45001 certifications, GDPR compliance, and a comprehensive pharmacovigilance system reporting to INFARMED, DGAV, and DGS.

Go-to-market is sales-led through direct commercial teams in Portugal and Morocco, with channel partnerships and licensing-out arrangements extending reach into 70+ countries. In 2020 the company acquired the Medicamenta Business Unit and in 2023 received external investment through Explorer Investments to fund R&D and production process improvements, signaling continued capital-supported growth in established therapeutic categories and selected adjacent areas such as Endocrinology and Respiratory.

Short descriptiontext

Grupo Medinfar is a Portuguese pharmaceutical company founded in 1970 that manufactures and markets own-brand and partnered pharmaceutical products across Consumer Health, Dermatology, Endocrinology, Respiratory, and Veterinary therapeutic areas, distributing to 70+ countries through 800+ product registrations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersAmadora, Portugal
HQ citystring
Amadora
HQ countrystring
Portugal
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, consumer health products, dermatology pharmaceuticals, contract manufacturing services, veterinary pharmaceuticals
Industry1 code
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Own Brand Pharmaceutical Products
TypeSubscription Recurring
Description

Manufacturing and marketing of company's own pharmaceutical brands, primarily in Consumer Health and Dermatology categories

explorerinvestments.com
2Partnered Brand Products
TypeTransaction Fee
Description

Manufacturing and marketing of products under partnership arrangements with other pharmaceutical companies

explorerinvestments.com
3Contract Manufacturing
TypeTransaction Fee
Description

Manufacturing pharmaceutical products for third-party clients under contract manufacturing agreements

explorerinvestments.com
4International Licensing Out
TypeLicensing Royalties
Description

Licensing products to partners in international markets where Medinfar manages regulatory registrations

medinfar.pt
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Medinfar is a Portuguese pharmaceutical company that manufactures and markets its own-branded and partnered pharmaceutical products across Consumer Health, Dermatology, Endocrinology, Respiratory and Veterinary therapeutic areas. The group operates an industrial manufacturing unit with Industry 4.0 capabilities, an R&D laboratory for new formulations, and a Qualified Person service, and manages 800+ product registrations in 70+ countries. Beyond branded products, it offers contract manufacturing for third parties and international licensing out of its registered products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 40 million units manufactured in 2023
+2 more records
Product overview1 text field

Medinfar is a Portuguese pharmaceutical company founded in 1970 that operates as a manufacturer and marketer of both proprietary and partnered pharmaceutical brands. The company operates as a platform of distinct branded products spanning Consumer Health, Dermatology, and specialized therapeutic areas. The portfolio includes branded products such as Trizatek, Otezia, Halibut Derma, Psoril, Halibut MF, Trikare, Oleoban, Xeratop, Provivax, Clique One, PreviPiQ, and Bio Ritmo. Medinfar's business model combines manufacturing capabilities (industrial unit), R&D (pharmaceutical development laboratory, analytical control services, Qualified Person services), and international distribution managing over 800 product registrations worldwide. The company also offers contract manufacturing services and operates in therapeutic areas including Consumer Health, Endocrinology, Respiratory, Dermatology, and Veterinary.

Product and service17 records
1Trizatek
CategoryConsumer Health / Dermatology pharmaceutical brand
Description

Branded pharmaceutical product marketed by Medinfar, part of the company's portfolio of consumer health and dermatology offerings.

2Otezia
CategoryPharmaceutical brand
Description

Branded pharmaceutical product in Medinfar's portfolio, distributed within Portugal and internationally.

3Halibut Derma
CategoryDermatology pharmaceutical brand
Description

Dermatology-focused branded product by Medinfar, positioned within the company's leading Consumer Health and Dermatology category in Portugal.

4Psoril
CategoryDermatology pharmaceutical brand
Description

Branded pharmaceutical product by Medinfar, included in the company's dermatology product range.

5Halibut MF
CategoryPharmaceutical brand
Description

Branded pharmaceutical product variant by Medinfar, part of the Halibut product line.

6Trikare
CategoryPharmaceutical brand
Description

Branded pharmaceutical product by Medinfar, included in the company's therapeutic portfolio.

7Oleoban
CategoryPharmaceutical brand
Description

Branded pharmaceutical product by Medinfar, distributed through the company's commercial network.

8Xeratop
CategoryConsumer Health pharmaceutical brand
Description

Branded pharmaceutical product by Medinfar, part of the company's consumer health offerings.

9Provivax
CategoryPharmaceutical brand
Description

Branded pharmaceutical product by Medinfar, included in the company's international product catalog.

10Clique One
CategoryPharmaceutical brand
Description

Branded pharmaceutical product by Medinfar, distributed in Portugal and internationally.

11PreviPiQ
CategoryConsumer Health pharmaceutical brand
Description

Branded pharmaceutical product by Medinfar, part of the company's preventive health portfolio.

12Bio Ritmo
CategoryConsumer Health pharmaceutical brand
Description

Branded pharmaceutical/health product by Medinfar, included in the company's consumer health offerings.

13Contract Manufacturing Services
CategoryContract manufacturing services
Description

Contract manufacturing service through Medinfar Manufacturing, S.A. for third-party pharmaceutical clients, leveraging the group's industrial unit, Industry 4.0 capabilities, ISO-certified quality systems, and capacity to produce multiple pharmaceutical forms.

14International Licensing Out
CategoryLicensing services
Description

International licensing of Medinfar-registered pharmaceutical products to local partners who manage commercialization in markets where Medinfar does not operate directly. Medinfar manages 800+ product registrations worldwide supporting this offering.

15Pharmaceutical Development Laboratory (R&D)
CategoryR&D laboratory services
Description

Pharmaceutical R&D laboratory service within the I&D division, focused on innovation of new products, processes and analytical methodologies, serving as a strategic area for the Group and for development of new solutions for clients.

16Analytical Control Services
CategoryAnalytical services
Description

Pharmaceutical analytical control services provided through the I&D division, supporting quality control, method development and analytical testing for pharmaceutical products.

17Qualified Person Services
CategoryRegulatory / quality services
Description

Qualified Person services providing certified pharmaceutical release oversight in accordance with EU GMP requirements, supporting batch certification and regulatory compliance for manufactured products.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOthers
Description

Partnership with respiratory disease patient association for disease prevention and management, contributing to reduced prevalence of chronic diseases in Portugal through appropriate treatment and counseling.

2MyOBESIDADE
Strategic tierCoreTypeOthers
Description

Partnership with obesity patient association for disease management and support, addressing chronic disease prevalence in Portugal.

medinfar.pt
Strategic tierCoreTypeOthers
Description

Partnership with Portuguese diabetes patient association for diabetes management and education, contributing to chronic disease awareness and treatment support.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnership network across 70+ countries for export and distribution of Medinfar products, managing local product registrations and commercialization.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Portuguese-headquartered pharmaceutical company with proprietary R&D and branded prescription products. Comparable to Medinfar as a fellow top-tier Portuguese pharma group competing for domestic market share and pursuing international commercialization.

TypeDirect peer
Description

Spanish dermatology-focused pharmaceutical company with branded prescription and consumer dermatology products across Europe. Directly comparable to Medinfar's dermatology leadership in Iberia and European commercial footprint.

TypeDirect peer
Description

Spanish pharmaceutical company with consumer health, OTC and branded prescription products including dermatology and respiratory. Highly comparable business model and Iberian market positioning to Medinfar.

TypeDirect peer
Description

Global dermatology-specialist pharmaceutical company. Comparable as the leading pure-play dermatology peer against which Medinfar's Halibut Derma and Psoril brands compete for shelf and prescription share.

TypeBroad incumbent
Description

European-focused generics and consumer healthcare company with broad portfolio across multiple therapeutic areas. Comparable as a much larger incumbent operating the same branded-generic-plus-consumer-health business model.

TypeBroad incumbent
Description

Global consumer healthcare and self-care products company focused on OTC, dermatology and store brands. Comparable as a benchmark for Medinfar's consumer health and OTC strategy at international scale.

TypeRegional player
Description

Italian pharmaceutical group with branded consumer health, OTC and specialty products across Europe. Comparable as a Southern European mid-cap pharma with similar diversified therapeutic and consumer health positioning.

TypeBroad incumbent
Description

European specialty pharmaceutical company with branded prescription and consumer health products. Comparable as a larger European incumbent with overlapping dermatology, endocrinology and respiratory portfolios.

TypeRegional player
Description

Italian pharmaceutical company with branded prescription, consumer health and chemical/pharma services businesses. Comparable as a Southern European pharma with parallel branded-plus-contract manufacturing model.

10Towa Pharmaceutical
TypeBroad incumbent
Description

International generics and contract development/manufacturing organization serving European and global markets. Comparable as a peer in pharmaceutical manufacturing services and generic distribution that competes for the same contract manufacturing opportunities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medinfar

Pharmaceuticalsmedinfar.pt

Grupo Medinfar is a Portuguese pharmaceutical company founded in 1970 that manufactures and markets own-brand and partnered pharmaceutical products across Consumer Health, Dermatology, Endocrinology, Respiratory, and Veterinary therapeutic areas, distributing to 70+ countries through 800+ product registrations.

What Medinfar does

Grupo Medinfar is a Portuguese-origin pharmaceutical company founded in 1970, headquartered in Amadora, Portugal, with direct operations in Portugal and Morocco and export reach to 70+ countries. The group manufactures and markets both proprietary and partnered pharmaceutical brands across therapeutic areas including Consumer Health, Dermatology, Endocrinology, Respiratory, and Veterinary, holding more than 800 product registrations worldwide and producing 40 million units in 2023. Its corporate structure spans wholly-owned subsidiaries covering manufacturing (Medinfar Manufacturing S.A.), consumer health (Medinfar Consumer Health Lda.), veterinary and immunological products (Medinfar Sorológico S.A.), generics (Genéricos Portugueses Lda.), and shared services (Medinfar Serviços Lda.). Medinfar holds the #1 position in Portugal in the Consumer Health and Dermatology category and ranks 3rd largest among Portugal's top 5 pharmaceutical companies.

The business model combines four revenue streams: own-brand pharmaceutical products (primarily in Consumer Health and Dermatology), partnered-brand manufacturing and marketing, contract manufacturing for third-party clients, and international licensing-out of products through local partners who manage in-country commercialization. Manufacturing is anchored by an industrial facility in Condeixa-a-Nova currently undergoing a €33.8M modernization under the Portugal 2030/COMPETE 2030 program, with €5.07M of EU co-financing, targeting €63M in post-expansion sales and the creation of 66 new jobs. In-house R&D focuses on new formulations, production processes, and analytical methodologies. Quality and regulatory infrastructure includes ISO 9001, 14001, and 45001 certifications, GDPR compliance, and a comprehensive pharmacovigilance system reporting to INFARMED, DGAV, and DGS.

Go-to-market is sales-led through direct commercial teams in Portugal and Morocco, with channel partnerships and licensing-out arrangements extending reach into 70+ countries. In 2020 the company acquired the Medicamenta Business Unit and in 2023 received external investment through Explorer Investments to fund R&D and production process improvements, signaling continued capital-supported growth in established therapeutic categories and selected adjacent areas such as Endocrinology and Respiratory.

Medinfar firmographics

Firmographics
Name
Medinfar
Legal name
Laboratório Medinfar – Produtos Farmacêuticos, S.A.
Website
https://medinfar.pt
Company type
Private
Founded year
1970
Operating status
Operating
Headcount range
251–500 employees
Short description
Grupo Medinfar is a Portuguese pharmaceutical company founded in 1970 that manufactures and markets own-brand and partnered pharmaceutical products across Consumer Health, Dermatology, Endocrinology, Respiratory, and Veterinary therapeutic areas, distributing to 70+ countries through 800+ product registrations.
Ownership category
akta.pro rank

Medinfar industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical manufacturing
  • Consumer health products
  • Dermatology pharmaceuticals
  • Contract manufacturing services
  • Veterinary pharmaceuticals

Where Medinfar is headquartered

Location

Headquarters

HQ city
Amadora
HQ country
Portugal
HQ region
Europe

Offices4 records

Markets served

Medinfar business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Own Brand Pharmaceutical Products: Manufacturing and marketing of company's own pharmaceutical brands, primarily in Consumer Health and Dermatology categories
  2. Partnered Brand Products: Manufacturing and marketing of products under partnership arrangements with other pharmaceutical companies
  3. Contract Manufacturing: Manufacturing pharmaceutical products for third-party clients under contract manufacturing agreements
  4. International Licensing Out: Licensing products to partners in international markets where Medinfar manages regulatory registrations

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Medinfar product offering

Product offering

Core offering

Medinfar is a Portuguese pharmaceutical company that manufactures and markets its own-branded and partnered pharmaceutical products across Consumer Health, Dermatology, Endocrinology, Respiratory and Veterinary therapeutic areas. The group operates an industrial manufacturing unit with Industry 4.0 capabilities, an R&D laboratory for new formulations, and a Qualified Person service, and manages 800+ product registrations in 70+ countries. Beyond branded products, it offers contract manufacturing for third parties and international licensing out of its registered products.

Product overview

Medinfar is a Portuguese pharmaceutical company founded in 1970 that operates as a manufacturer and marketer of both proprietary and partnered pharmaceutical brands. The company operates as a platform of distinct branded products spanning Consumer Health, Dermatology, and specialized therapeutic areas. The portfolio includes branded products such as Trizatek, Otezia, Halibut Derma, Psoril, Halibut MF, Trikare, Oleoban, Xeratop, Provivax, Clique One, PreviPiQ, and Bio Ritmo. Medinfar's business model combines manufacturing capabilities (industrial unit), R&D (pharmaceutical development laboratory, analytical control services, Qualified Person services), and international distribution managing over 800 product registrations worldwide. The company also offers contract manufacturing services and operates in therapeutic areas including Consumer Health, Endocrinology, Respiratory, Dermatology, and Veterinary.

Differentiator

Problem solved

Functional benefit

Products and services

  • Trizatek Branded pharmaceutical product marketed by Medinfar, part of the company's portfolio of consumer health and dermatology offerings.
  • Otezia Branded pharmaceutical product in Medinfar's portfolio, distributed within Portugal and internationally.
  • Halibut Derma Dermatology-focused branded product by Medinfar, positioned within the company's leading Consumer Health and Dermatology category in Portugal.
  • Psoril Branded pharmaceutical product by Medinfar, included in the company's dermatology product range.
  • Halibut MF Branded pharmaceutical product variant by Medinfar, part of the Halibut product line.
  • Trikare Branded pharmaceutical product by Medinfar, included in the company's therapeutic portfolio.
  • Oleoban Branded pharmaceutical product by Medinfar, distributed through the company's commercial network.
  • Xeratop Branded pharmaceutical product by Medinfar, part of the company's consumer health offerings.
  • Provivax Branded pharmaceutical product by Medinfar, included in the company's international product catalog.
  • Clique One Branded pharmaceutical product by Medinfar, distributed in Portugal and internationally.
  • PreviPiQ Branded pharmaceutical product by Medinfar, part of the company's preventive health portfolio.
  • Bio Ritmo Branded pharmaceutical/health product by Medinfar, included in the company's consumer health offerings.
  • Contract Manufacturing Services Contract manufacturing service through Medinfar Manufacturing, S.A. for third-party pharmaceutical clients, leveraging the group's industrial unit, Industry 4.0 capabilities, ISO-certified quality systems, and capacity to produce multiple pharmaceutical forms.
  • International Licensing Out International licensing of Medinfar-registered pharmaceutical products to local partners who manage commercialization in markets where Medinfar does not operate directly. Medinfar manages 800+ product registrations worldwide supporting this offering.
  • Pharmaceutical Development Laboratory (R&D) Pharmaceutical R&D laboratory service within the I&D division, focused on innovation of new products, processes and analytical methodologies, serving as a strategic area for the Group and for development of new solutions for clients.
  • Analytical Control Services Pharmaceutical analytical control services provided through the I&D division, supporting quality control, method development and analytical testing for pharmaceutical products.
  • Qualified Person Services Qualified Person services providing certified pharmaceutical release oversight in accordance with EU GMP requirements, supporting batch certification and regulatory compliance for manufactured products.

Quantifiable outcome

  • 40 million units manufactured in 2023
  • +2 more outcomes

Companies that use Medinfar

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Medinfar technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Medinfar partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • RESPIRAcoreOthersPartnership with respiratory disease patient association for disease prevention and management, contributing to reduced prevalence of chronic diseases in Portugal through appropriate treatment and counseling.
  • MyOBESIDADEcoreOthersPartnership with obesity patient association for disease management and support, addressing chronic disease prevalence in Portugal.
  • APDP (Associação Protectora dos Diabéticos de Portugal)coreOthersPartnership with Portuguese diabetes patient association for diabetes management and education, contributing to chronic disease awareness and treatment support.
  • International DistributorscoreChannel Partner/ Reseller/ DistributorPartnership network across 70+ countries for export and distribution of Medinfar products, managing local product registrations and commercialization.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Medinfar competitors and assessment

Company assessment

Direct peers

  • Bial: Portuguese-headquartered pharmaceutical company with proprietary R&D and branded prescription products. Comparable to Medinfar as a fellow top-tier Portuguese pharma group competing for domestic market share and pursuing international commercialization.
  • Almirall: Spanish dermatology-focused pharmaceutical company with branded prescription and consumer dermatology products across Europe. Directly comparable to Medinfar's dermatology leadership in Iberia and European commercial footprint.
  • Faes Farma: Spanish pharmaceutical company with consumer health, OTC and branded prescription products including dermatology and respiratory. Highly comparable business model and Iberian market positioning to Medinfar.
  • Galderma: Global dermatology-specialist pharmaceutical company. Comparable as the leading pure-play dermatology peer against which Medinfar's Halibut Derma and Psoril brands compete for shelf and prescription share.

Broad incumbents

  • Stada Arzneimittel: European-focused generics and consumer healthcare company with broad portfolio across multiple therapeutic areas. Comparable as a much larger incumbent operating the same branded-generic-plus-consumer-health business model.
  • Perrigo: Global consumer healthcare and self-care products company focused on OTC, dermatology and store brands. Comparable as a benchmark for Medinfar's consumer health and OTC strategy at international scale.
  • Recordati: European specialty pharmaceutical company with branded prescription and consumer health products. Comparable as a larger European incumbent with overlapping dermatology, endocrinology and respiratory portfolios.
  • Towa Pharmaceutical: International generics and contract development/manufacturing organization serving European and global markets. Comparable as a peer in pharmaceutical manufacturing services and generic distribution that competes for the same contract manufacturing opportunities.

Regional players

  • Rottapharm: Italian pharmaceutical group with branded consumer health, OTC and specialty products across Europe. Comparable as a Southern European mid-cap pharma with similar diversified therapeutic and consumer health positioning.
  • Zambon: Italian pharmaceutical company with branded prescription, consumer health and chemical/pharma services businesses. Comparable as a Southern European pharma with parallel branded-plus-contract manufacturing model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Medinfar compliance and trust

Trust signal

Compliance5 records

Medinfar financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medinfar leadership team

Management profile

Number of profiles

Medinfar subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Medinfar funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medinfar M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medinfar

What does Medinfar do?

Medinfar is a Portuguese pharmaceutical company that manufactures and markets its own-branded and partnered pharmaceutical products across Consumer Health, Dermatology, Endocrinology, Respiratory and Veterinary therapeutic areas. The group operates an industrial manufacturing unit with Industry 4.0 capabilities, an R&D laboratory for new formulations, and a Qualified Person service, and manages 800+ product registrations in 70+ countries. Beyond branded products, it offers contract manufacturing for third parties and international licensing out of its registered products.

Is Medinfar a public or private company?

Medinfar is a private company. It is classified as venture growth investor backed and is currently operating.

When was Medinfar founded?

Medinfar was founded in 1970. It employs 251 to 500 people.

Where is Medinfar based?

Medinfar is headquartered in Amadora, Portugal, in the Europe region.

How does Medinfar make money?

Four revenue lines are on record. Own Brand Pharmaceutical Products are the primary driver. The others are partnered Brand Products, contract Manufacturing and international Licensing Out.

Who are Medinfar's main competitors?

Direct peers on record are Bial, Almirall, Faes Farma and Galderma. Broad incumbents are Stada Arzneimittel, Perrigo, Recordati and Towa Pharmaceutical. Regional players are Rottapharm and Zambon.

Does Medinfar have an API?

No public API is recorded for Medinfar.

What industry is Medinfar in?

Medinfar's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals